SONN — Sonnet Biotherapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $26.33m
- $26.01m
- $0.02m
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Sonnet’S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer
Brief: Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan
Brief: Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas
Brief: Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer
Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.39 a share - Earnings Preview
Brief: Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance Of EU Patent For Fhab® Platform Technology
Brief: Sonnet Biotherapeutics Files For Offering Of Up To 2 Million Shares Of Common Stock
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
Sonnet Biotherapeutics Holdings Inc expected to post a loss of $5.52 a share - Earnings Preview
Sonnet Biotherapeutics Holdings Inc expected to post a loss of $5.52 a share - Earnings Preview
Brief: Sonnet Biotherapeutics Announces Issuance Of US Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Brief: Sonnet Biotherapeutics Regains Compliance With Nasdaq
Brief: Sonnet Biotherapeutics Enters Into Licensing Agreement With Alkem Laboratories
Brief: Sonnet Biotherapeutics Announces 1-For-8 Reverse Stock Split